Hematology is one of the areas in which active interactions and mutual stimulations between clinical medicine and basic science have been producing remarkable progress. We are trying to obtain deeper insights into mechanisms of and develop effective treatments for various hematological diseases, with a motto, “from bedside to bench, from bench to bedside”.
Research and EducationWe perform our research, focusing on “cure” of hematological malignancies and infectious diseases, by bidirectional approaches, that is, from bedside to bench, and from bench to bedside. Our research extends over both basic science and clinical medicine in hematology, immunology and virology, and covers diverse fields as follows: 1) basic and clinical research on the pathophysiology and the treatment of hematological malignancies including leukemia, MDS, lymphoma, myeloma and ATL, 2) basic and clinical research on oncogenic mechanisms mediated by APOBEC3-induced genome mutagenesis and the impaired DNA repair systems in cancer cells, 3) application of iPS cell technology to basic and clinical research on hematological disorders and regenerative medicine of the blood, 4) basic and clinical research on the pathophysiology of infectious diseases including HIV, and host defense against them, 5) basic and clinical research on dendritic cells and tumor immunotherapy, and 6) basic and clinical research on hematopoietic stem cell transplantation and cellular immunotherapy. By these researches, we aim to elucidate the pathophysiology of hematological malignancies and infectious diseases, thereby develop novel diagnostics and therapeutic strategies and apply them to clinical practice.
(Picture) Department members （April, 2019）
- Jo T, Nishikori M, Kogure Y, Arima H, Sasaki K, Sasaki Y, Nakagawa T, Iwai F, Momose S, Shiraishi A, Kiyonari H, Kagaya N, Onuki T, Shin-Ya K, Yoshida M, Kataoka K, Ogawa S, Iwai K and Takaori-Kondo A. LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. 136(6):684-697, 2020.
- Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, Kanda J, Ishikawa T, Imada K, Ueda Y, Toda Y, Anzai N, Yago K, Nohgawa M, Yonezawa A, Tsunemine H, Itoh M, Yamamoto K, Tsuji M, Moriguchi T, Takaori-Kondo A and Kyoto Stem Cell Transplantation G. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv. 4(13):3169-3179, 2020.
- Otsuka Y, Nishikori M, Arima H, Izumi K, Kitawaki T, Hishizawa M and Takaori-Kondo A. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol. 119:35-45, 2020.
- Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M, Sarca AD, Kazuma Y, Matsui H, Maruyama W, Fukuda H, Shirakawa R, Shindo K, Ri M, Iida S and Takaori-Kondo A. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells. Sci Rep. 9(1):7122, 2019.
- Hirabayashi S, Bhagat S, Matsuki Y, Takegami Y, Uehata T, Kanemaru A, Itoh M, Shirakawa K, Takaori-Kondo A, Takeuchi O, Carninci P, Katayama S, Hayashizaki Y, Kere J, Kawaji H and Murakawa Y. NET-CAGE characterizes the dynamics and topology of human transcribed cis-regulatory elements. Nat Genet. 51(9):1369-1379, 2019.
Hematology and OncologyProfessor: Akifumi Takaori-Kondo
Associate Professor: Kouhei Yamashita
Senior Lecturer: Tadakazu Kondo
Senior Lecturer: Momoko Nishikori
Assistant Professor: Toshio Kitawaki
Assistant Professor: Takero Shindo
Assistant Professor: Kotaro Shirakawa
Assistant Professor: Junya Kanda
Assistant Professor: Takashi Sakamoto
Assistant Professor: Akihiro Imura
Assistant Professor: Kazuhisa Chonabayashi
Assistant Professor: Chisaki Mizumoto
Assistant Professor: Yasuyuki Arai (Department of Transfusion and Cell Therapy)